Insight Molecular Diagnostics Inc. (formerly OncoCyte Corporation): Business Overview, Financials & Competitive Analysis
Insight Molecular Diagnostics Inc. (formerly OncoCyte Corporation) scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage diagnostic company with promising transplant testing platform and growing pharma services revenue, but requires successful clinical trial execution and FDA clearance to validate its $1B market opportunity thesis.
What is Insight Molecular Diagnostics Inc. (formerly OncoCyte Corporation)'s industry? Insight Molecular Diagnostics Inc. (formerly OncoCyte Corporation) (oncocyte.com) operates in Precision Diagnostics / Medical Device Testing (Cancer & Transplant Rejection Monitoring). AskCyborg classifies Insight Molecular Diagnostics Inc. (formerly OncoCyte Corporation) under Precision Diagnostics / Medical Device Testing (Cancer & Transplant Rejection Monitoring) in its company registry.
OncoCyte is a precision diagnostics and monitoring company focused on improving cancer patient outcomes through advanced testing solutions. The company is capturing value in the estimated $1 billion total addressable ...
Cyborg Score thesis
Early-stage diagnostic company with promising transplant testing platform and growing pharma services revenue, but requires...
Read the full analyst-debate transcript →Get the Latest Insight Molecular Diagnostics Inc. (formerly OncoCyte Corporation) Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeInsight Molecular Diagnostics Inc. (formerly OncoCyte Corporation) Overview
Pro stress-test →OncoCyte is a precision diagnostics and monitoring company focused on improving cancer patient outcomes through advanced testing solutions. The company is capturing value in the estimated $1 billion total addressable market for transplant rejection testing, while maintaining a clinical oncology portfolio.
Strategic Profile
Pro stress-test →The company is rebranding itself to better align with its broader market focus on both transplant and oncology diagnostics. OncoCyte has completed the design of its clinical molecular diagnostic testing kit and secured approval from a major institutional review board, with plans to involve three of the top ten U.S. transplant centers in an upcoming clinical trial.
Competitive Landscape
Pro stress-test →OncoCyte competes in the precision diagnostics space against companies like Guardant Health, Guardant Health, Zymo Research, and others focused on liquid biopsy and transplant monitoring. Its differentiation lies in transplant rejection testing with a defined $1B TAM and partnerships with major transplant centers, though it remains an earlier-stage entrant compared to established cancer diagnostic players.
Industry Context
Insight Molecular Diagnostics Inc. (formerly OncoCyte Corporation) operates in Precision Diagnostics / Medical Device Testing (Cancer & Transplant Rejection Monitoring).
Key facts
Founded: 2009 · Headquarters: Nashville, Tennessee · Employees: N/A · Revenue: $2.1M (Q1 2025) · Market cap: N/A